Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older (there is no maximum age limit)
- You are able to carry out basic daily activities and are not fully disabled (your doctor will assess this using a standard scale — confirm with trial site)
- You have been confirmed by a lab test (from a tissue or fluid sample) to have a type of cancer called adenocarcinoma, located in the stomach or where the stomach meets the food pipe
- Your kidneys and blood counts are at acceptable levels — including white blood cells, infection-fighting cells (neutrophils), platelets, and a measure of kidney function called creatinine (your doctor will check these)
- Your cancer has spread to the lining of the abdomen (peritoneum), either shown by a positive fluid test or seen during a surgical procedure
Who may not be able to join:
- Your cancer has spread to organs other than the abdominal lining, such as the liver, brain, or lungs
- You currently have an active infection, such as pneumonia or a wound infection, that could interfere with treatment
- You are pregnant or breastfeeding; women who could become pregnant must agree to use an acceptable form of contraception during the study (confirm with trial site)
- You have unstable chest pain (angina) or moderate-to-severe heart failure
- You are not able or willing to follow the study procedures and required follow-up visits
- You have had a severe or life-threatening allergic reaction in the past to the chemotherapy drugs used in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess improvements in survival in gastric adenocarcinoma patients with occult or apparent carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.